Tourmaline Bio, Inc.

Tourmaline Bio, Inc. (TRML) Market Cap

Tourmaline Bio, Inc. has a market capitalization of $1.23B.

Price: $47.98

0.00 (0.00%)

Market Cap: 1.23B

NASDAQ · time unavailable

CEO: Sandeep C. Kulkarni

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2021-05-07

Website: https://www.tourmalinebio.com

Tourmaline Bio, Inc. (TRML) - Company Information

Market Cap: 1.23B|Sector: Healthcare

Company Profile

Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.

Analyst Sentiment

54%
Hold

From 8 Active Polls

1Y Forecast: $48.50

▲ +1.1% Potential Upside

Consensus Target Metrics

Low Bound

$48

Median

$48

High Bound

$50

Average

$49

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$48.50
▲ +1.08% Upside
Low Target
$47.50
-1% Risk
Median Target
$48.00
0% Mid
High Target
$50.00
4% Max
Consensus
Hold
1 / 10 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Period EndingTrailing 12MJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
Market Cap ($M)1,233412391523662328567419571
Enterprise Value ($M)1,201381356493628258469279505
Price to Earnings Ratio (P/E)-26.80-4.44-4.27-5.90-8.24-4.68-10.70-8.08-20.66
Price/Earnings-to-Growth Ratio (PEG)
Price to Sales Ratio (P/S)13078.57184.08
Price to Book Ratio (P/B)4.771.591.401.742.060.971.602.044.00
Price to Free Cash Flow Ratio (P/FCF)-29.38-20.32-18.02-25.03-28.26-18.20-37.9938.01-21.75
Enterprise Value to Sales (EV/Sales)12322.02122.43
Enterprise Value to EBITDA (EV/EBITDA)-24.55-14.65-15.49-22.18-25.70-11.74-26.79-18.73-61.17
Debt to Equity Ratio0.640.000.000.000.000.000.000.000.00

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 TOURMALINE BIO INC (TRML) — Investment Overview

🧩 Business Model Overview

Tourmaline (TRML) is an upstream energy producer focused on developing and producing natural gas and natural gas liquids (NGLs) in North America. The economic engine is a cycle of (1) acquiring and controlling resources in productive basins, (2) drilling and completing wells to convert subsurface reserves into production, and (3) monetizing output through a mix of firm sales, spot exposure, and downstream-linked pricing mechanisms. Because production requires ongoing infrastructure (gathering, processing, transportation and storage arrangements), the business model also depends on keeping operating flows connected to takeaway capacity and minimizing downtime and field-level costs.

💰 Revenue Streams & Monetisation Model

Revenue primarily comes from sales of natural gas and NGLs, typically with pricing tied to North American benchmark indexes and basis differentials that reflect geographic location and contract terms. NGL monetization usually benefits from fractionation and marketing arrangements that allow higher-value liquids to be captured alongside gas volumes. Margin drivers are (1) realized pricing net of transportation and processing costs, (2) field-level operating costs (including compression, power and chemicals), and (3) capital efficiency—how effectively drilling converts reserves into production and cash flow over the life of assets.

While upstream revenue is inherently volume and price sensitive, the monetization model can exhibit stability when firms maintain durable takeaway access and manage basis exposure through contract design and scheduling discipline.

🧠 Competitive Advantages & Market Positioning

Tourmaline’s moat is best characterized as geographic cost advantage supported by logistical infrastructure and scale-driven operational capability.

  • Geographic cost advantage / low-cost feedstock access: Positioning in prolific North American gas basins can lower delivered costs relative to producers that require longer-distance transportation or face weaker basin economics.
  • Logistical infrastructure: Midstream connectivity—through gathering systems, processing and arrangement of transportation—reduces basis risk and helps keep volumes flowing to markets that clear at favorable terms.
  • Operational scale and learning: Repeatable drilling and completion programs, standardization of field processes, and established supply chains can improve well performance and lower unit costs.

Competitive benchmarking:

  • Ovintiv (broad upstream exposure across multiple basins): broader geographic mix can diversify commodity risk, but basin-specific cost advantages depend on asset quality and infrastructure access.
  • ARC Resources (large Canadian gas/LNG-relevant exposure): also competes for productive basin acreage and infrastructure; differentiation depends on drilling economics and how effectively each operator locks in processing and transportation terms.
  • Canadian Natural Resources (heavier weighting toward oil sands and liquids): competes more through broader commodity exposure and capital allocation, rather than matching Tourmaline’s focus on gas- and NGL-linked basin economics.

Tourmaline’s industry focus is anchored more directly in North American gas and associated liquids, which places emphasis on basin-level cost structure and transportation/processing execution rather than relying primarily on oil-weighted revenue streams.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the value creation framework tends to follow three themes: (1) resource conversion, (2) market access and basis, and (3) demand growth for gas and gas-derived products.

  • Continued development of basin resources: Sustained drilling programs and optimization of well design can expand recoverable volumes, extending asset lives and sustaining production profiles.
  • North American gas demand and export optionality: Power generation, industrial heating, and additional LNG and pipeline-linked export capacity can increase structural demand for North American gas and support realized pricing relative to constrained regions.
  • NGL recovery and product mix: Liquids yield improvements and better capture of NGL value can lift margins even when gas pricing is volatile.
  • Infrastructure-led resilience: Owning or effectively controlling infrastructure pathways can reduce volume loss and improve realized prices through better basis positioning.

⚠ Risk Factors to Monitor

  • Commodity price volatility: Natural gas and NGL pricing can swing materially due to storage levels, weather, and global supply dynamics.
  • Regulatory and environmental pressure: Methane emissions rules, carbon pricing, water management requirements and permitting timelines can increase operating and capital costs.
  • Takeaway constraints and basis risk: Pipeline and processing capacity limitations can reduce realized pricing and constrain volumes.
  • Capital intensity and execution risk: Upstream growth requires disciplined drilling efficiency; underperformance in well productivity or higher-than-expected costs can impair returns.
  • Interest rate and credit conditions: E&P cash flow sensitivity can affect refinancing costs and investment flexibility.

📊 Valuation & Market View

The sector is typically valued using cash-flow-based frameworks, with emphasis on EV/EBITDA (or EV/EBITDAX), DCF models, and free cash flow sensitivity to commodity prices and transportation differentials. Valuation outcomes generally hinge on:

  • Production growth quality: growth driven by durable basin economics and scalable infrastructure rather than episodic, high-cost expansions.
  • Unit cost trajectory: operating cost discipline and capital efficiency (cost per unit of production growth).
  • Balance sheet strength and reinvestment capacity: the ability to sustain development through commodity cycles.
  • Hedge posture and basis management: realized pricing stability and reduced volatility of cash margins.

🔍 Investment Takeaway

Tourmaline’s investment case rests on a structural advantage in North American gas development: a basin-linked low-cost feedstock positioning amplified by logistical infrastructure and execution discipline that supports resilient unit economics. In this framework, long-term returns depend less on headline commodity cycles and more on maintaining cost leadership, protecting takeaway/basis positioning, and converting resource advantage into production and free cash flow through disciplined capital allocation.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

14 Stories Available

Real-time institutional reporting and market updates for TRML.

globenewswire.com2025-10-28

Novartis completes acquisition of Tourmaline Bio

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis.

globenewswire.com2025-10-28

Novartis announces expiration of Tourmaline Bio tender offer

Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding, expired at one minute following 11:59 p.m., Eastern Time, on October 27, 2025 (the “Expiration Date”).

globenewswire.com2025-10-22

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding. The expiration of the HSR Act waiting period occurred at 11:59 p.m., Eastern Time, on October 21, 2025.    Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of September 8, 2025 (the “Merger Agreement”), among Novartis, Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), and Tourmaline, including the tender offer and the subsequent merger, which remain subject to the condition that there be validly tendered and not validly withdrawn in accordance with the terms of the offer, immediately prior to the Expiration Date (as defined below) a number of Shares that, together with any Shares then owned by Novartis or any of its direct or indirect wholly owned subsidiaries, represents at least a majority of Shares outstanding at the time of expiration of the offer. The offer will expire at one minute following 11:59 p.m., Eastern Time, on October 27, 2025, unless the offer is otherwise extended (such date or subsequent date to which the expiration of the offer is extended in accordance with the terms of the Merger Agreement, the “Expiration Date”) or earlier terminated in accordance with the Merger Agreement.

businesswire.com2025-10-06

Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

globenewswire.com2025-09-29

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding. Such offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September 29, 2025, and the related Letter of Transmittal (together, the “Offer”) and pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of September 8, 2025 (the “Merger Agreement”), among Novartis, Purchaser and Tourmaline.

prnewswire.com2025-09-15

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

businesswire.com2025-09-11

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

zacks.com2025-09-10

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

investopedia.com2025-09-09

This Small Biotech Stock Is Surging Today. Here's Why.

Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.

seekingalpha.com2025-09-09

Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal

Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highlighting confidence in Tourmaline's cardiovascular drug pipeline.

businesswire.com2025-09-09

TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Tourmaline Bio, Inc. (NASDAQ: TRML) to Novartis AG for $48.00 per share in cash is fair to Tourmaline shareholders. Halper Sadeh encourages Tourmaline shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Tourmaline.

proactiveinvestors.co.uk2025-09-09

Novartis strikes $1.4bn deal for Tourmaline Bio

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The Swiss pharmaceutical group will pay $48.00 a share, a 59% premium to Tourmaline's closing price on Monday and 127% above its 60-day average.

businesswire.com2025-09-09

Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible breaches of fiduciary duty and other violations of law in its transaction with a Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Tourmaline will $48.00 per share in cash at closing, or a total equity value of approximately $1.4 billio.

reuters.com2025-09-09

Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion

Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-06-30

"TRML is currently pre-revenue and reported a net loss of approximately $23.1M as of June 30, 2025. With 25.8 million shares outstanding, the company does not have a market capitalization as its share price is currently listed as zero. The firm has total assets of approximately $269.3M and total liabilities of $10.1M, resulting in a substantial equity base of about $259.2M. The company's net debt position is positive, implying a cash position after liabilities. However, negative operating cash flow of $20.3M underscores ongoing financial challenges. The firm has not paid dividends recently. Without revenue generation and substantial losses, TRML faces significant hurdles in growth and profitability, limiting its overall appeal. Investor sentiment remains neutral due to the lack of performance metrics, and without additional capital or operational advancements, the company's situation could be precarious."

Revenue Growth

Neutral

No revenue reported.

Profitability

Neutral

Significant net loss of $23.1M indicates profitability concerns.

Cash Flow Quality

Neutral

Negative operating cash flow shows poor cash management.

Leverage & Balance Sheet

Positive

Strong balance sheet with positive equity and minimal liabilities.

Shareholder Returns

Neutral

No returns as there are no dividends and losses reported.

Analyst Sentiment & Valuation

Neutral

Lack of market performance data limits analysis.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for TRML.

SEC EDGAR Live Feed
No recent 10-K available.
No recent 10-Q available.
Loading financial data and tables...
📁

SEC Filings (TRML)

© 2026 Stock Market Info — Tourmaline Bio, Inc. (TRML) Financial Profile